Figure 2.
Figure 2. Phenotype of HHV8-specific cells according to the outcome of infection. (A) Tetramer+ cells were compared for the presence of CD45RA, CCR7, and CD27 markers in 14 patients from whom enough material was available (□ indicates 6 patients without KS; ▪, 7 patients with ongoing KS; and ▦, 5 patients in KS remission). The histograms show the percentages of tetramer+ cells (grouped data) with the markers indicated (mean ± SEM). (B) Flow cytometric analysis of CD45RA and CCR7 or CD27 coexpression gated on CD8+ tetramer+ cells. Each display represents results from a representative patient in each group. (C) Intracellular perforin content was determined in tetramer+ cells. Dot plots are gated on live CD8 T cells and show tetramer and perforin staining. The percentages indicated in the quadrants are representative of grouped data for patients without KS (median, 63%; range, 12%-99%), patients in KS remission (median, 48%; range, 25%-88%, nonsignificant), and patients with ongoing KS (median, 33%; range, 13%-66%, P = .04 for comparison with patients without KS).

Phenotype of HHV8-specific cells according to the outcome of infection. (A) Tetramer+ cells were compared for the presence of CD45RA, CCR7, and CD27 markers in 14 patients from whom enough material was available (□ indicates 6 patients without KS; ▪, 7 patients with ongoing KS; and ▦, 5 patients in KS remission). The histograms show the percentages of tetramer+ cells (grouped data) with the markers indicated (mean ± SEM). (B) Flow cytometric analysis of CD45RA and CCR7 or CD27 coexpression gated on CD8+ tetramer+ cells. Each display represents results from a representative patient in each group. (C) Intracellular perforin content was determined in tetramer+ cells. Dot plots are gated on live CD8 T cells and show tetramer and perforin staining. The percentages indicated in the quadrants are representative of grouped data for patients without KS (median, 63%; range, 12%-99%), patients in KS remission (median, 48%; range, 25%-88%, nonsignificant), and patients with ongoing KS (median, 33%; range, 13%-66%, P = .04 for comparison with patients without KS).

Close Modal

or Create an Account

Close Modal
Close Modal